|
gptkbp:instanceOf
|
gptkb:drug
small molecule
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2008
|
|
gptkbp:ATCCode
|
gptkb:B02BX05
|
|
gptkbp:bioavailability
|
52%
|
|
gptkbp:brand
|
gptkb:Promacta
gptkb:Revolade
|
|
gptkbp:CASNumber
|
496775-61-2
|
|
gptkbp:chemicalFormula
|
biphenyl hydrazone derivative
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:discoveredBy
|
GlaxoSmithKline
|
|
gptkbp:drugClass
|
thrombopoietin receptor agonist
|
|
gptkbp:eliminationHalfLife
|
21-32 hours
|
|
gptkbp:genericName
|
no (as of 2024)
|
|
gptkbp:hasMolecularFormula
|
C25H22N4O4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
eltrombopag
|
|
gptkbp:KEGGID
|
D08913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
thrombopoietin receptor agonist
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
442.47 g/mol
|
|
gptkbp:patentExpired
|
2027
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:PubChem_CID
|
9846183
CHEMBL1201736
DB06210
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
fatigue
headache
thromboembolic events
liver enzyme elevation
|
|
gptkbp:UNII
|
Q1J0S2TZ4D
|
|
gptkbp:usedFor
|
thrombocytopenia
chronic immune thrombocytopenia
severe aplastic anemia
thrombocytopenia in hepatitis C
|
|
gptkbp:bfsParent
|
gptkb:Promacta
gptkb:Revolade
|
|
gptkbp:bfsLayer
|
5
|